why choose us

First received: May 23, 2023

Clinical Trial: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Dedifferentiated Liposarcoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma

Brief Summary: Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced).In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be removed surgically (unresectable).The purpose of this study is to find out whether the combination of etrumadenant and zimberelimab is an effective treatment for people with advanced DDLS.

Read more